Oncology competition spotlights non-medical solutions that can close patient-support gap
Pharma has struggled to align patient services with the needs of disease communities. Open innovation represents one approach towards closing the gap.
Most recent articles by Marc Iskowitz
6 takeaways from HLTH 2019
A half-dozen takeaways from MM&M executive editor Marc Iskowitz’s two days in Las Vegas — which felt more like five.
Pharma, trying to transform itself, but must get out of its own way first, says Novartis digital chief
Chief digital officers from three of the biggest pharmas discussed success and failure in the clinical and commercial settings this week at HLTH.
Facebook, medical associations launch preventive health tool
The social giant says information collected will be stored securely, with controls on advertising.
Amazon’s second healthcare acquisition is emblematic of the kinds of digital solutions becoming startup exits
As private money flows into often buzzy, consumer-facing digital health startups, the firms getting bought or going public often make tools designed to be used behind the scenes.
As Sandoz returns marketing rights for digital therapeutics to Pear, what does it mean for co-promote arrangements?
Sandoz is relinquishing the marketing reins 18 months after agreeing to co-promote. More broadly, what does it mean for commercializing this nascent technology?
Marketing is fueling the march toward precision oncology, says Caris chief commercial officer
Oncology is moving toward a future in which treatments are genetically matched to patients’ tumors. But we won’t get there without generating a lot more awareness about molecular diagnostics, says Caris’ commercial chief.
Has CME put a dent in the opioid crisis? The jury’s still out
Despite 900 courses and 500,000 learners, the effort has missed the mark on some core goals.
What’s causing the widening gender gap in healthcare marketing? What’s the fix?
MM&M executive editor Marc Iskowitz addresses healthcare marketing’s snowballing pay gap.
J&J lays out defense strategy for Ohio opioid trial. It feels familiar
Trial briefs filed yesterday by drug makers and other defendants revealed arguments to be used in the upcoming trial.
